AGP Executive Report
Last update: 4 hours agoCannabinoid & CBD Policy/Legal: A hemp company is pushing back against a DEA position that a synthetic-from-plant cannabinoid (HHC) is federally illegal, arguing the agency’s “technical” classification change still undermines its stance in ongoing court fights. Clinical CBD/Cannabinoid Research: Neurotech International reported clinically meaningful outcomes from a randomized, placebo-controlled paediatric cannabinoid study in children with autism spectrum disorder, and also secured a cultivation partnership to lock in the genetics behind its standardized drug candidate. Medical Cannabis Business: Emyria landed a payer agreement with a major Australian private insurer to fund eligible members’ supervised clinic-based psychedelic-assisted and cannabinoid-based mental health treatment. Medicinal Cannabis Markets: Incannex won a new US patent for its obstructive sleep apnoea combination therapy, extending offshore exclusivity, while Little Green Pharma expanded its ASX-quoted share base as it scales cultivation, manufacturing and export. Drug Enforcement (CBD-adjacent): Nigeria’s NDLEA destroyed about 329,865kg of illicit drugs in Lagos valued around ₦301bn, including multiple cannabis strains, as part of a court-ordered exercise. Hemp Industry (Regulation): New Zealand’s Hemp Industries Association launched a Seed Project for the 2026 season after rule changes removed a licensing barrier for low-THC industrial hemp growers.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
